Ambry Genetics Unveils Decade-Long Genetic Study to Advance Healthcare Equity
Reuters
Oct 20
Ambry Genetics Unveils Decade-Long Genetic Study to Advance Healthcare Equity
Ambry Genetics, a leader in genetic testing and a wholly owned subsidiary of Tempus AI, Inc. $(TEM)$, announced the publication of a peer-reviewed study in Genetics in Medicine highlighting the impact of proactive exome reanalysis for healthcare equity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251016919374) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.